Sage Therapeutics
SAGE
SAGE was delisted on the 30th of July, 2025.
269 hedge funds and large institutions have $7.61B invested in Sage Therapeutics in 2018 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 114 increasing their positions, 77 reducing their positions, and 28 closing their positions.
68% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 28
48% more repeat investments, than reductions
Existing positions increased: 114 | Existing positions reduced: 77
17% more funds holding in top 10
Funds holding in top 10: 12 → 14 (+2)
7% more funds holding
Funds holding: 251 → 269 (+18)
5% more call options, than puts
Call options by funds: $61.1M | Put options by funds: $58M
0.51% more ownership
Funds ownership: 103.93% → 104.44% (+0.51%)
1% less capital invested
Capital invested by funds: $7.66B → $7.61B (-$46.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$74.8M |
| 2 |
Millennium Management
New York
|
+$51.4M |
| 3 |
Fiera Capital (Canada)
Montreal,
Quebec, Canada
|
+$38.2M |
| 4 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
+$34.7M |
| 5 |
JP Morgan Chase
New York
|
+$33.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$154M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$45.1M |
| 3 |
VOYA Investment Management
Atlanta,
Georgia
|
-$43.8M |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$42.6M |
| 5 |
State Street
Boston,
Massachusetts
|
-$37M |
SAGE Hedge Fund Activity: Q2 2018 in Review
269 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q2 2018, worth a combined $7.61B — down 0.6% from $7.66B a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new SAGE positions and 28 closed out — a net gain of 19 holders — while 114 added to existing stakes and 77 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $74.8M. The largest seller was BlackRock, cutting an estimated $154M.
- 269 institutional investors held Sage Therapeutics (SAGE) as of Q2 2018, up from 251 in Q1 2018.
- Funds reported $7.61B of Sage Therapeutics stock for Q2 2018, down 0.6% quarter-over-quarter.
- 47 funds opened new Sage Therapeutics positions in Q2 2018 and 28 closed out, a net change of +19 holders.
- The largest Sage Therapeutics buyer in Q2 2018 was T. Rowe Price Associates, an estimated $74.8M added.
- The largest Sage Therapeutics seller in Q2 2018 was BlackRock, an estimated $154M sold.
Based on aggregated 13F filings for Q2 2018.